These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35552528)

  • 1. Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.
    Weiden PJ; Breier A; Kavanagh S; Miller AC; Brannan SK; Paul SM
    J Clin Psychiatry; 2022 May; 83(3):. PubMed ID: 35552528
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
    Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
    Kaul I; Sawchak S; Walling DP; Tamminga CA; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    JAMA Psychiatry; 2024 Aug; 81(8):749-756. PubMed ID: 38691387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.
    Sauder C; Allen LA; Baker E; Miller AC; Paul SM; Brannan SK
    Transl Psychiatry; 2022 Nov; 12(1):491. PubMed ID: 36414626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
    Azargoonjahromi A
    Clin Drug Investig; 2024 Jul; 44(7):471-493. PubMed ID: 38904739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia.
    Correll CU; Angelov AS; Miller AC; Weiden PJ; Brannan SK
    Schizophrenia (Heidelb); 2022 Dec; 8(1):109. PubMed ID: 36463237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
    Horan WP; Targum SD; Claxton A; Kaul I; Yohn SE; Marder SR; Miller AC; Brannan SK
    Schizophr Res; 2024 Dec; 274():57-65. PubMed ID: 39260339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial.
    Targum SD; Murphy C; Breier A; Brannan SK
    J Psychiatr Res; 2021 Dec; 144():241-246. PubMed ID: 34700212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
    Breier A; Brannan SK; Paul SM; Miller AC
    Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review.
    Leber A; Ramachandra R; Ceban F; Kwan ATH; Rhee TG; Wu J; Cao B; Jawad MY; Teopiz KM; Ho R; Le GH; Ramachandra D; McIntyre RS
    Expert Opin Pharmacother; 2024 Mar; 25(4):467-476. PubMed ID: 38515004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
    J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.
    Marder S; Fleischhacker WW; Earley W; Lu K; Zhong Y; Németh G; Laszlovszky I; Szalai E; Durgam S
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):127-136. PubMed ID: 30470662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial.
    Brown HE; Freudenreich O; Fan X; Heard SO; Goff D; Petrides G; Harrington AL; Kane JM; Judge H; Hoeppner B; Fava M; Perlis RH
    JAMA Psychiatry; 2019 Jul; 76(7):691-699. PubMed ID: 30916714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
    Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
    CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of HP-3070, an Asenapine Transdermal System, on Symptoms of Hostility in Adults With Schizophrenia: A Post Hoc Analysis of a 6-Week Phase 3 Study.
    Citrome L; Komaroff M; Starling B; Byreddy S; Terahara T; Hasebe M
    J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35687858
    [No Abstract]   [Full Text] [Related]  

  • 20. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.